UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy

Aug.11.2022
UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy
The Welsh Tobacco Control Strategy lacks support for e-cigarettes and misses a significant opportunity for smoking cessation, says UKVIA.

The newly released Tobacco Control Strategy (TCS) in Wales has stated that it has not yet developed a position on e-cigarettes. The UKVIA has stated that, given the support of e-cigarettes in other parts of the UK, it will continue to engage with Welsh policymakers.


A plan to reduce smoking rates in Wales and achieve a "smoke-free" status by 2030 has been recently released. However, the plan has been criticized by the UK Vaping Industry Association (UKVIA) for lacking support for electronic cigarettes, which they describe as a missed opportunity. The UKVIA is the largest industry association representing the e-cigarette industry in the United Kingdom.


John Dunne, CEO of UKVIA stated, "While there are many commendable aspects to the strategy for reducing smoking rates in Wales, it is disappointing that the Welsh government hasn't gone further to seize this golden opportunity to embrace and advocate for e-cigarettes as the best and most effective way to help people quit smoking for good.


Although the Welsh TCS did mention e-cigarettes, it was only briefly noted that the Welsh government needs to develop its stance on e-cigarettes.


Dunne went on to say, "For this reason, we will continue to collaborate with the Welsh government, as in the recent example of the Khan review on smoking, which concluded that promoting e-cigarettes is absolutely crucial for achieving a smoke-free UK by 2030.


Welsh TCS has brought up the issue of preventing children and young people from smoking and using e-cigarettes - a topic that UKVIA has strongly advocated for. Dunne stated: "We welcome the Welsh government's plan to prevent young people from accessing e-cigarettes.


As an association, we have called on the UK government to impose stricter regulations on e-cigarette retailers who sell to young people. We recommend a fine of £10,000 for those caught in violation.


Returning to Wales, TCS lacks support for e-cigarettes as a tool to quit smoking. Dunne added, "There is indisputable evidence that e-cigarettes are effective in helping adults quit smoking. Support is growing among the scientific, academic, healthcare, and political communities, all of which now recognize e-cigarettes as an important component in helping smokers quit.


While it is disappointing to see that the Welsh government has not taken a more proactive stance on e-cigarettes, it is important to engage with politicians and decision-makers in the region to showcase the value of these devices and help the country achieve its smoke-free goals. Failing to do so could have serious consequences for Wales' ability to reduce smoking rates and minimize harm.


Meanwhile, in Scotland, a survey of 2,170 individuals found that 41% of respondents reported that e-cigarettes helped them quit smoking. The survey also found that only one-sixth of respondents wished for stricter regulations on e-cigarettes, while half hoped for more relaxed regulations. Scotland's government is currently considering whether to ban in-store promotions of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals for educational and informational purposes only.


This article does not necessarily represent the views of 2FIRSTS, and 2FIRSTS cannot verify the truth or accuracy of the article's content. The translation of this article is intended only for internal industry discussion and research purposes.


Due to limitations in translation skills, the translated article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regard to any domestic, Hong Kong, Macao, Taiwan, or foreign statements and positions.


All compiled information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
IVG Parent Secures HMRC Excise Warehouse and Duty Stamp Approvals Ahead of UK Vape Tax
Acme Vape Ltd, the company behind UK vaping brand IVG, has received HM Revenue & Customs approval to operate an excise warehouse for vaping products and participate in the Vaping Duty Stamps Scheme. The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Acme Vape Ltd says its approved warehouse in Preston will become operational under the new regime on the same date.
Regulations
Sep.18 by 2Firsts Perspectives
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23